Curious about today's AI digest?ai-tldr.dev
Pomegra LogoPomegra

Daily Digest

BriefMarket · bullishHigh impact
Esc

Roivant Sciences Stock Jumps 24% on Record PHocus Trial Result

GlobeNewsWire2 min read6 sources

Why is Roivant Sciences stock up today?

Roivant Sciences (ROIV) stock jumped as much as 24% on Tuesday after Pulmovant's PHocus trial showed mosliciguat cut pulmonary vascular resistance 56.3% — a record for any controlled pulmonary hypertension study.

Key numbers

PVR Reduction (Week 16)-56.3%placebo-adjusted (p<0.0001); highest ever in any controlled PH trial [1]
6-Minute Walk Distance (Week 16)+35.2 metersvs. ~15-meter decline in placebo group (p=0.0027) [1]
NT-proBNP Reduction (Week 24, exploratory)-75.9%expanded from -53.2% at Week 16; nominal p<0.0001 [1]
ROIV Close (Sep 8, 2026)$41.48+18.75% on the day; intraday all-time high $42.50 (+24%) [2]
Analyst Price Targets (post-trial)$46–$55TD Cowen to $55; Jefferies $42 to $52 (Buy); Guggenheim $42 to $46 (Buy) [3][4][6]
PH-ILD Patient Market~200,000US and Europe; median survival 1.5–2 years with current standard of care [1]

What happened

Roivant Sciences (ROIV) stock jumped as much as 24% on Tuesday after Pulmovant's PHocus trial showed mosliciguat cut pulmonary vascular resistance 56.3% — a record for any controlled pulmonary hypertension study. The Phase 2 PHocus enrolled 135 patients at 87 sites in 20 countries; mosliciguat also improved walking ability by 35.2 meters and cut a heart-stress marker (NT-proBNP) by 53.2% at Week 16, both statistically significant. Shares closed at $41.48 (+18.75%) after hitting an all-time high of $42.50 intraday, as Roivant disclosed its Phase 3 PHrontier trial for PH-ILD is already enrolling up to 375 patients. Jefferies raised its price target from $42 to $52; TD Cowen moved to $55; Guggenheim lifted to $46.

Why it matters

Roivant Sciences' result matters because PH-ILD — pulmonary hypertension caused by progressive lung scarring — kills most patients within 1.5 to 2 years of diagnosis, and no drug is approved specifically for it. A 56.3% drop in pulmonary vascular resistance is more than double what analysts had projected, suggesting mosliciguat could become the first approved therapy for a market of up to 200,000 patients in the US and Europe. If Phase 3 PHrontier confirms this result, Roivant could be in FDA approval discussions within a few years.

Who this affects

Marketbullish
High impact
Biotech stocks gain as rare-disease drug delivers record trial result.
Companybullish
High impact
Roivant shareholders gained roughly $4.4B in market value.
Competitorsbearish
Medium impact
Gossamer Bio's rival PH-ILD program faces a sharply higher bar.
Industrybullish
High impact
PH-ILD field gains its first record-shattering pulmonary vascular resistance result.

Roivant Sciences vs United Therapeutics, Liquidia

Roivant SciencesROIV$29.6B+18.75%$42.50—
United TherapeuticsUTHR$21.6B—$609.3519.5x
LiquidiaLQDA$6.1B—$93.61—

As of 2026-09-10

How we got here

  1. Roivant announces PHocus results to be presented at ERS Congress 2026

  2. PHocus topline data presented at ERS 2026; Phase 3 PHrontier enrollment disclosed underway

  3. ROIV surges 24% intraday to all-time high $42.50; closes up 18.75% at $41.48

  4. Jefferies, TD Cowen, Guggenheim, H.C. Wainwright all raise ROIV price targets

What to watch

  • Phase 3 PHrontier readout — 375-patient global PH-ILD trial now enrolling2028–2029
  • FDA expedited designation (Breakthrough Therapy or Fast Track) for mosliciguat2027
  • Next wave of analyst price target revisions following PHocus dataQ4 2026

Educational content only. Not investment advice.

More briefsAll briefs →